To compare the efficacy and safety of edoxaban and warfarin for treatment of portal vein thrombosis (PVT) following danaparoid sodium in patients with liver cirrhosis.
Results: There were no significant differences in the clinical characteristics of patients in the two groups. Treatment with edoxaban reduced the volume of PVT from 1.42 cm 3 at 2 weeks to 0.42 cm 3 at 6 months, and prevented exacerbation of PVT at 6 months after treatment with danaparoid sodium (P = 0.016).
In contrast, treatment with warfarin resulted in increased PVT volume from 1.73 cm 3 at 2 weeks to 2.85 cm 3 at 6 months, despite the control of the international normalized ratio in 57% of the patients (P = 0.005). Multivariate regression analysis identified edoxaban therapy as the single significant and independent determinant of PVT reduction at 6 months (P = 0.0014, hazard ratio 6.400). Clinically significant gastrointestinal bleeding was encountered in 3 of 20 (15%) patients of the edoxaban group and 2 of 30 (7%) of the warfarin group (P = 0.335).
Conclusion:
Edoxaban following danaparoid sodium is an effective anticoagulant and could be potentially considered as one of the treatment options for PVT in cirrhotic patients.
INTRODUCTION
P ORTAL VEIN THROMBOSIS (PVT) is a frequent event in liver cirrhosis. The reported incidence of PVT in compensated disease ranges from 0.6% to 5%, but the incidence increases up to 26% with advanced liver disease. [1] [2] [3] [4] The expected pathophysiological consequences of PVT are further increase in portal hypertension and worsening of liver function due to decreased portal flow.
The role of PVT in the development of major complications of cirrhosis, such as gastrointestinal bleeding, deterioration of liver function and mortality, remains to be established. [5] [6] [7] [8] [9] Derangement of the liver architecture and subsequent slowing of portal blood flow have been considered the main pathogenetic factors of PVT in cirrhotic patients. 1 Portal vein thrombosis itself is a multifactorial pathology, involving both local inflammatory foci and systemic prothrombotic factors. The pathogenetic factors of PVT are similar to those long recognized for venous thromboembolism: damage to the vessel wall, slowing of blood flow, and hypercoagulability. The last of these three factors can be defined as a procoagulant imbalance due to increased plasma levels of coagulation factors caused by acquired disorders, such as cancer and inflammation, or inherited thrombophilia. 10 Portal vein thrombosis is classified as either chronic or acute. In patients with liver cirrhosis, PVT is virtually always of the chronic type. Furthermore, gastrointestinal bleeding, development or abrupt worsening of ascites, and/or hepatic encephalopathy are often associated with the onset of PVT; such complications have a significant negative impact on overall prognosis. Thus, cirrhosis is one of the important risk factors of PVT, and careful management of PVT is necessary in the overall clinical care of patients with cirrhosis.
Generally, treatment of PVT is initiated with unfractionated heparin or low-molecular-weight heparin, and then switched to oral anticoagulation with warfarin. 11 Unfortunately, warfarin is limited by a narrow therapeutic window and a highly variable dose-response requiring frequent dose adjustments and monitoring. Recently, Naeshiro et al. 12 reported the efficacy and safety of anticoagulation therapy with danaparoid sodium in cirrhotic patients with PVT. Danaparoid sodium used for the treatment of pulmonary embolism and deep vein thrombosis in the cardiovascular field is a heparinoid glycosaminoglycuronan antithrombotic agent. The risk of bleeding in patients on danaparoid is relatively low, in comparison with heparin. The anticoagulation effect of danaparoid, which is highly selective for anti-Xa activity, is superior to heparin. 13, 14 However, danaparoid must be given intravenously and it is difficult to continue its use in the outpatient setting. Furthermore, the above studies were case reports of successful treatment of PVT with the new oral anticoagulant. [15] [16] [17] Thus, the standard treatment for cirrhosis-related PVT has yet to be established.
In this study, we investigated the efficacy and safety of the new oral anticoagulant edoxaban as maintenance therapy for PVT treated with danaparoid sodium. Edoxaban, a direct factor Xa inhibitor with predictable pharmacokinetics, 18, 19 is rapidly absorbed to achieve peak blood levels in 1-2 h, and approximately 50% of the edoxaban absorbed dose is excreted by the kidneys. 20 In this retrospective study, we compared the effects of edoxaban and warfarin for PVT in patients with liver cirrhosis following danaparoid sodium. 
METHODS

Patients
Treatment protocol for PVT
Cirrhotic patients with PVT were first treated with danaparoid sodium (Orgaran; MSD, Tokyo, Japan), 2500 units/day for 2 weeks by i.v. infusion. Treatment was supplemented with Anthrobin P, an antithrombin III (CSL Behring, Tokyo, Japan; Japan Blood Products Organization, KENKETSU Nonthron, Tokyo, Japan; Nihon Pharmaceutical, Tokyo, Japan), for 3 days at 1500 units/day i.v. in those patients whose antithrombin III activity decreased by less than 70%. Subsequently, patients received warfarin at a dose adjusted to achieve an international normalized ratio (INR) of 1.5-2.0 until November 2014, and edoxaban at 60 mg once daily after December 2014. The edoxaban dose was halved to 30 mg once daily in patients with creatinine clearance of 30-50 mL/min, patients with body weight of ≤60 kg, and patients who were on concurrent treatment with a strong P-glycoprotein inhibitor. Treatment with edoxaban and warfarin continued for up to 6 months.
Esophageal and gastric varices were examined endoscopically before treatment. Patients found to have F2 or F3 and/or RC1 or RC2/3 varices were treated by endoscopic injection sclerotherapy or endoscopic variceal ligation before anticoagulation therapy. All patients underwent imaging studies and blood tests (hepatic reserve test, platelet count, and coagulation/fibrinolytic system) and were monitored closely for complications before and during treatment of PVT.
Evaluation of response to therapy
All patients underwent contrast-enhanced computed tomography (CT) to evaluate the response to treatment of PVT. With the use of the paintbrush tool of the Advantage Workstation (version 4.2; GE Healthcare, Tokyo, Japan), an image processing apparatus, we traced the area around PVT in the axial view of the contrastenhanced CT. The volume of PVT was computed by the Advantage Workstation. The measurement was confirmed by a radiology technologist and the physician. Based on the PVT volume reduction rate [= {(PVT volume before treatment À volume after treatment) / (PVT volume before treatment)} ×100], the response to treatment was categorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Complete response was defined as complete disappearance of the PVT (PVT reduction rate = 100%), PR as PVT volume reduction rate of ≥50% to <100%, SD as reduction rate <50%, and PD as increase in the PVT volume after treatment, in comparison with pretreatment volume of the thrombus.
Follow-up
All 50 patients underwent regular clinical follow-up including blood tests and dynamic CT at 2 weeks, 1 month, 3 months, and 6 months of PVT treatment.
Statistical analysis
Results are expressed as median and range values. Comparisons of categorical variables were carried out using the χ 2 -test. Factors that influenced PVT volume reduction rate were assessed by the Mann-Whitney U-test and Wilcoxon rank-sum test, where applicable. All P-values are two-tailed, and P < 0.05 was considered 
RESULTS
Clinical characteristics
T HE CLINICAL CHARACTERISTICS of patients treated with edoxaban and warfarin were not significantly different (Table 1 ). In the edoxaban group, PVT was localized in the main trunk of the portal vein in 15 patients (75%), intrahepatic portal branch in 2 (10%), superior mesenteric vein in 1 (5%), and splenic vein in 1 (5%). In the warfarin group, PVT was localized in the main trunk of the portal vein in 26 patients (87%), intrahepatic portal branch in 2 (7%), superior mesenteric vein in 1 (3%), and splenic vein in 1 (3%). There was no significant difference in localization of PVT between the two groups.
Effects of edoxaban treatment on PVT
Among patients of the edoxaban group, 16 patients had creatinine clearance of 30-50 mL/min or body weight ≤60 kg. Accordingly, 16 patients were treated with 30 mg once daily whereas the other 4 were treated with 60 mg once daily. Figure 1 illustrates the effects of danaparoid sodium followed by edoxaban treatment on PVT. The median volume of PVT after the completion of 2 weeks of treatment with danaparoid sodium (1.42 cm 3 ) was significantly smaller than that before the treatment (3.43 cm 3 , P = 0.002). The median volumes of PVT measured after 1, 3, and 6 months of treatment with edoxaban were 1.34, 0.96, and 0.42 cm 3 , respectively. At 6 months, edoxaban significantly reduced the volume of PVT (P = 0.016; Fig. 1a ). Figure 1(b) shows the effects of danaparoid sodium followed by warfarin treatment on PVT. The median volume of PVT at baseline was 3.74 cm 3 and diminished significantly after 2 weeks of treatment with danaparoid sodium to 1.73 cm 3 (P = 0.024). We also measured changes in PVT volume at 1, 3, and 6 months induced by treatment with warfarin. The median PVT volumes were 1.64, 1.37, and 2.85 cm 3 , respectively. The PVT volume after 6 months of treatment with warfarin was significantly larger than that after treatment with danaparoid sodium (P = 0.005) (Fig. 1b) .
Effects of warfarin treatment for PVT
We also examined the effect of the dose of warfarin on PVT volume that could or could not achieve INR control. After 6 months of treatment, INR control was achieved in 57% of the patients, as shown in Table 2; despite INR control, PVT was significantly exacerbated at 6 months.
Comparison of efficacy of edoxaban and warfarin
We compared changes in PVT at 6 months between the edoxaban and warfarin groups. Treatment with edoxaban for 6 months resulted in a significant reduction in PVT volume. In contrast, 6 months of treatment with warfarin resulted in significant worsening of the PVT volume (P < 0.001; Table 3 ). These results were associated with a Figure 1 Volume of portal vein thrombosis in patients with liver cirrhosis treated with danaparoid sodium for 2 weeks then edoxaban (a) or warfarin (b). Volumes were measured before treatment, then after 2 weeks, 1 month, 3 months, and 6 months of treatment. significantly higher CR in the edoxaban group than the warfarin group (P < 0.001).
Results of univariate and multivariate analyses of factors associated with reduction of PVT at 6 months
Univariate analysis showed that successful reduction of PVT correlated significantly with the use of edoxaban and prothrombin activity (>70%). Multivariate analysis that included the above two parameters identified treatment with edoxaban as the only independent determinant of reduction of PVT (hazard ratio, 6.400; 95% confidence interval, 1.455-28.151; P = 0.0014) ( Table 4 ).
Safety and adverse effects
Using the Common Terminology Criteria for Adverse Events version 4.0 for adverse events, grade 3/4 adverse events were recognized in 5 (10%) of all 50 patients (gastrointestinal bleeding). Of them, 3 (15%) of 20 patients were in the edoxaban group, and 2 (7%) of 30 patients were in the warfarin group.
In the edoxaban group, the following complications were noted during treatment: rectal varices in 1, angiodysplasia of the small intestine in 1, and colon polyps in 1 patient. All 3 patients with bleeding received low-dose edoxaban (30 mg once daily). No other complications of grade 3/4 were recognized. Furthermore, no gastrointestinal bleeding or other side-effects were observed in patients with Child-Pugh grade B or C. In the warfarin group, 2 patients developed esophageal varices. These patients stopped oral administration. The adverse events of patients treated with edoxaban and warfarin were not significantly different. Patients with esophageal and rectal variceal bleeding were treated with endoscopic variceal ligation, colon polyps were treated with endoscopic mucosal resection, and angiodysplasia of the small intestine was treated with polidocanol injection for vascular lesions. Hemostasis was obtained in all patients.
Overall, there were no significant differences in adverse events between the two groups. Furthermore, none of the patients of either group developed liver dysfunction or symptoms of anaphylaxis throughout the study.
DISCUSSION
I
N THE PRESENT study, we assessed the efficacy and safety of edoxaban and warfarin following treatment with danaparoid sodium for PVT in patients with liver cirrhosis. The main findings were that 2 weeks of treatment with danaparoid sodium reduced PVT in all patients. These results are similar to those reported previously, 12 confirming that danaparoid sodium is safe and effective for the treatment of PVT in patients with liver cirrhosis. Subsequent treatment with edoxaban significantly reduced the volume of PVT and this effect was observed at 1, 3, and 6 months, with a CR rate at 6 months of 70%. Among the warfarin group, the volume of PVT was exacerbated at 6 months, and the CR at 6 months was only 20%. Our results indicate that edoxaban is more suitable for longterm maintenance therapy of PVT.
Portal vein thrombosis is the most common thrombotic phenomenon in patients with cirrhosis. Venous stasis in the portal vein, resulting from splanchnic pooling and architectural derangement of the liver, is thought to be one of the main pathophysiological factors of PVT. 21 In addition, imbalance between pro-and anticoagulant factors is important, as well as various conditions that cause a hypercoagulable state, and inherited or acquired thrombophilia. 22 Recent in vivo studies showed a hypercoagulable state in patients with cirrhosis, mainly due to high levels of factor VIII and low levels of protein C, depending on the severity of the liver disease. Apart from the mechanisms precipitating PVT, the role of PVT in the development of major complications of cirrhosis, such as gastrointestinal bleeding, worsening of liver function and mortality remains to be established.
At present, PVT is usually first treated with unfractionated heparin or low-molecular-weight heparin then treatment is subsequently switched to oral warfarin. 11 In this study, among the warfarin group, we selected an INR target of 1.5-2.0 during treatment, taking into consideration the potential risk of bleeding in patients with cirrhosis. Unfortunately, although INR was controlled in more than half of the patients at 6 months of treatment, treatment with warfarin caused significant worsening of PVT. As expected, the use of warfarin is limited by a narrow therapeutic window; the treatment is often associated with extensive food and drug interactions and a highly variable dose-response, thus requiring frequent dose adjustments and monitoring. At the present stage, it is not clear whether it is appropriate to maintain the INR within the target range of 1.5-2.0 in patients with cirrhosis. In PVT treatment with warfarin, it may be necessary to set a higher target range of INR, such as that used in the treatment for atrial fibrillation. Further investigation is necessary.
Anticoagulant therapy is an important treatment strategy for patients with cirrhosis and PVT. However, the use of low-molecular-weight heparin and warfarin in patients with cirrhosis and PVT was considered suitable in previous studies that included only a small number of patients. In these studies, the rate of complete recanalization ranged from 36% to 60% after 3 months and increased to 75% in those patients who continued anticoagulant treatment beyond 6 months. [24] [25] [26] Other reports described the successful treatment of patients with PVT by rivaroxaban, a new oral anticoagulant. [15] [16] [17] In these studies, patients with cirrhosis and mild hepatic impairment, classified as Child-Pugh A, showed only minor changes in rivaroxaban pharmacokinetics, similar to the matched healthy control subjects. However, cirrhotic patients with moderate hepatic impairment, classified as Child-Pugh B and C, showed increased pharmacodynamic effects of rivaroxaban, probably due to coagulopathy and clinically relevant increased risk of bleeding associated with hepatic disease. 27, 28 For this reason, we chose the new oral anticoagulant, edoxaban, for treatment because it is not subjected to hepatic metabolism.
Two recent studies 29, 30 concluded that edoxaban (given once daily after initial treatment with heparin) can be an alternative to warfarin in patients with venous thromboembolism. In these studies, the therapeutic effects of edoxaban were found to be equivalent to those of highquality standard therapy. It was also reported that edoxaban caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including patients with severe pulmonary embolism, suggesting it could be useful for patients with liver cirrhosis classified as Child-Pugh B and C.
However, there are some limitations to the use of edoxaban in daily clinical practice. For example, the dose of edoxaban must be adjusted in patients with low body weight and also in those with renal dysfunction. Furthermore, as the risk of bleeding is unknown, care should be taken during treatment with edoxaban to diagnose and treat any potential bleeding, especially gastrointestinal bleeding. Further studies are needed to determine the effects of edoxaban on prognosis, especially in patients with Child-Pugh grade B and C, and also its thrombolytic effects. 7, 31 This is important as cirrhotic patients are at high risk of bleeding following the initiation of new oral anticoagulation therapy. 32 Edoxaban was an effective drug without the need for monitoring. However, there is a possibility that the risk of gastrointestinal bleeding may increase even without the need for monitoring. It should be noted that, although no significant difference was observed, 15% of patients had gastrointestinal bleeding in the edoxaban group. In the warfarin group, two patients developed esophageal varices bleeding despite of F1 varices. The risk of gastrointestinal bleeding occurs constantly in both treatment modalities, so it is necessary to confirm esophageal and gastric varices or bleeding lesions before ingesting an oral anticoagulation therapy. Furthermore, prophylactic treatment may be necessary even if there is little risk of bleeding.
Finally, the question of how long PVT treatment should continue is considered an important point. Currently, anticoagulation for at least 3 months is recommended in the guidelines of the American Association for the Study of Liver Disease to allow recanalization to occur, and to avoid intestinal infarction and worsening of portal hypertension. 33 Delgad et al. proposed that anticoagulation should be maintained indefinitely to prevent re-thrombosis. 34 Therefore, in terms of the time period of this study, because the reduction effect of PVT was satisfactory, we think that treatment is necessary for at least 6 months and is necessary in the long term after disappearance of PVT. At the same time, it is necessary to pay great attention to serious complications such as gastrointestinal bleeding. However, at this time, a definite treatment period is not clear, and we think that accumulation of cases is necessary.
We recently introduced in-hospital treatment with danaparoid sodium because it is given as an i.v. injection twice a day. However, the time at which edoxaban reaches peak serum concentration is 1 h with 30 mg oral administration, and both edoxaban and danaparoid sodium have immediate effects. 35 Therefore, we think that it is desirable to introduce edoxaban at initial treatment for PVT in the future. Appropriate selection of oral anticoagulation therapy is considered to be a future subject.
The present study has certain limitations. The study was retrospective in design and included a limited number of patients. Moreover, the results do not allow us to conclude that the effects of edoxaban are better than those of warfarin, but we believe that the present study revealed the beneficial effects edoxaban in patients with cirrhosis complicated with PVT.
In conclusion, our results showed that edoxaban following danaparoid sodium was effective, suggesting it can be potentially used as one of the treatment options for PVT in patients with cirrhosis.
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